PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Rhea-AI Summary

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its fourth quarter and full-year 2024 financial results and operational highlights announcement for Wednesday, February 12, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss results and provide business updates. Management recommends participants register at least 5 minutes before the call starts. Those not planning to ask questions are advised to join via webcast.

News Market Reaction – PYPD

+2.05%

1 alert

+2.05% News Effect

On the day this news was published, PYPD gained 2.05%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

	Date:	Wednesday, February 12, 2025
	Time:	8:30 AM Eastern Time
	Conference
	Call:	https://register.vevent.com/register/BI4e72dffa5a7b4167a28a33a6b3097df3
	Webcast	https://edge.media-server.com/mmc/p/7uzqoye3

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 

PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
Britchie@lifesciadvisors.com

FAQ

When will PolyPid (PYPD) release its Q4 and full-year 2024 earnings?

PolyPid will release its Q4 and full-year 2024 financial results before U.S. markets open on Wednesday, February 12, 2025.

What time is PolyPid's (PYPD) Q4 2024 earnings call?

PolyPid's Q4 2024 earnings conference call is scheduled for 8:30 AM Eastern Time on Wednesday, February 12, 2025.

How can investors join PolyPid's (PYPD) Q4 2024 earnings call?

Investors can join via conference call by registering through the provided link or listen to the webcast through the company's media server link.

How early should participants register for PolyPid's (PYPD) Q4 2024 earnings call?

PolyPid recommends participants register at least 5 minutes before the start of the call to ensure proper connection.